PDF herunterladen
Int J Angiol 2011; 20(4): 213-222
DOI: 10.1055/s-0031-1295520
REVIEW ARTICLE

© Thieme Medical Publishers

Atherosclerosis: Current Status of Prevention and Treatment

Thomas F. Whayne1
  • 1Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
09. November 2011 (online)

   Lizenzen und Reprints
Preview

ABSTRACT

The reality of regression of atherosclerotic plaques was established as long ago as 1987 by aggressive cholesterol reduction even before the era of statin therapy. Nevertheless, the most important aspect of patient benefit to prevent cardiovascular (CV) disease events is stabilization of these plaques so they will not rupture. Lowering of low-density lipoproteins is critical to this goal and can be considered the gold standard of preventive CV medicine. The major goal for the high-risk patient and the diabetic patient is lowering these harmful lipoproteins to less than 70 mg/dL. No discussion of CV disease prevention is complete without considering tobacco abuse and its elimination. Even secondhand smoke has been established as harmful. Control of hypertension is another major aspect of CV disease prevention, and a blood pressure less than 120/80 mm Hg is ideal. With obesity a major problem in the developed world, its role in the metabolic syndrome is of major significance as is the high prevalence of this so-called syndrome versus collection of specific risk factors in a population with poor health habits. Control of diabetes mellitus has established benefit from the standpoint of CV disease prevention except that some problems have been reported with extremely tight blood sugar control. Exercise was long considered good but now there are evidence-based reasons to recommend it as essential in CV disease prevention. There are many unforeseen frontiers in CV disease prevention but, for now, everything points to elevation of high-density lipoproteins as the next focus of this prevention.

KEYWORDS

Atherosclerosis - coronary heart disease - peripheral vascular disease - cholesterol - statins

REFERENCES

  • 1 The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.  JAMA. 1984;  251 (3) 351-364
    Suche in Google Scholar
  • 2 The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.  JAMA. 1984;  251 (3) 365-374
    Suche in Google Scholar
  • 3 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 (8934) 1383-1389
    Suche in Google Scholar
  • 4 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Engl J Med. 1998;  339 (19) 1349-1357
    Suche in Google Scholar
  • 5 Downs J R, Clearfield M, Weis S et al.. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 1998;  279 (20) 1615-1622
    Suche in Google Scholar
  • 6 Sacks F M, Pfeffer M A, Moye L A et al.. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.  N Engl J Med. 1996;  335 (14) 1001-1009
    Suche in Google Scholar
  • 7 Shepherd J, Cobbe S M, Ford I West of Scotland Coronary Prevention Study Group et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.  N Engl J Med. 1995;  333 (20) 1301-1307
    Suche in Google Scholar
  • 8 Liao J K, Laufs U. Pleiotropic effects of statins.  Annu Rev Pharmacol Toxicol. 2005;  45 89-118
    Suche in Google Scholar
  • 9 Libby P. Molecular bases of the acute coronary syndromes.  Circulation. 1995;  91 (11) 2844-2850
    Suche in Google Scholar
  • 10 Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.  Stroke. 2006;  37 (7) 1923-1932
    Suche in Google Scholar
  • 11 Nissen S E, Nicholls S J, Sipahi I ASTEROID Investigators et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.  JAMA. 2006;  295 (13) 1556-1565
    Suche in Google Scholar
  • 12 Blankenhorn D H, Johnson R L, Nessim S A, Azen S P, Sanmarco M E, Selzer R H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.  Control Clin Trials. 1987;  8 (4) 356-387
    Suche in Google Scholar
  • 13 Blankenhorn D H, Nessim S A, Johnson R L, Sanmarco M E, Azen S P, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.  JAMA. 1987;  257 (23) 3233-3240
    Suche in Google Scholar
  • 14 Blankenhorn D H, Selzer R H, Mack W J et al.. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.  Circulation. 1992;  86 (6) 1701-1709
    Suche in Google Scholar
  • 15 Brown B G, Zhao X Q, Chait A et al.. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.  N Engl J Med. 2001;  345 (22) 1583-1592
    Suche in Google Scholar
  • 16 Brown G, Albers J J, Fisher L D et al.. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.  N Engl J Med. 1990;  323 (19) 1289-1298
    Suche in Google Scholar
  • 17 Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism.  Atherosclerosis. 2007;  192 (2) 313-322
    Suche in Google Scholar
  • 18 Falk E, Shah P K, Fuster V. Coronary plaque disruption.  Circulation. 1995;  92 (3) 657-671
    Suche in Google Scholar
  • 19 Sacks F M, Svetkey L P, Vollmer W M DASH-Sodium Collaborative Research Group et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet.  N Engl J Med. 2001;  344 (1) 3-10
    Suche in Google Scholar
  • 20 Kastorini C M, Milionis H J, Esposito K, Giugliano D, Goudevenos J A, Panagiotakos D B. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals.  J Am Coll Cardiol. 2011;  57 (11) 1299-1313
    Suche in Google Scholar
  • 21 Estruch R, Martínez-González M A, Corella D PREDIMED Study Investigators et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial.  Ann Intern Med. 2006;  145 (1) 1-11
    Suche in Google Scholar
  • 22 Fitó M, Guxens M, Corella D for the PREDIMED Study Investigators et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial.  Arch Intern Med. 2007;  167 (11) 1195-1203
    Suche in Google Scholar
  • 23 Grundy S M, Cleeman J I, Merz C N National Heart, Lung, and Blood Institute et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.  Circulation. 2004;  110 (2) 227-239
    Suche in Google Scholar
  • 24 Wiviott S D, Cannon C P, Morrow D A, Ray K K, Pfeffer M A, Braunwald E. PROVE IT-TIMI 22 Investigators . Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.  J Am Coll Cardiol. 2005;  46 (8) 1411-1416
    Suche in Google Scholar
  • 25 Hsia J, MacFadyen J G, Monyak J, Ridker P M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).  J Am Coll Cardiol. 2011;  57 (16) 1666-1675
    Suche in Google Scholar
  • 26 Kastelein J J, Akdim F, Stroes E S ENHANCE Investigators et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia.  N Engl J Med. 2008;  358 (14) 1431-1443
    Suche in Google Scholar
  • 27 Ridker P M, Danielson E, Fonseca F A JUPITER Study Group et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;  359 (21) 2195-2207
    Suche in Google Scholar
  • 28 Whayne Jr T F, Zielke J C, Dickson L G, Winters J L. State of the art treatment of the most difficult low density lipoprotein (LDL) cholesterol problems: LDL apheresis.  J Ky Med Assoc. 2002;  100 (12) 535-538
    Suche in Google Scholar
  • 29 Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.  Cardiovasc Drug Rev. 2003;  21 (3) 199-215
    Suche in Google Scholar
  • 30 Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service: Superintendent of Documents, U.S. Government Printing Office, Washington, D.C., 20402. 1964: 1-387
    Suche in Google Scholar
  • 31 Ambrose J A, Barua R S. The pathophysiology of cigarette smoking and cardiovascular disease: an update.  J Am Coll Cardiol. 2004;  43 (10) 1731-1737
    Suche in Google Scholar
  • 32 Benowitz N L. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment.  Prog Cardiovasc Dis. 2003;  46 (1) 91-111
    Suche in Google Scholar
  • 33 Jha P, Jacob B, Gajalakshmi V RGI-CGHR Investigators et al. A nationally representative case-control study of smoking and death in India.  N Engl J Med. 2008;  358 (11) 1137-1147
    Suche in Google Scholar
  • 34 Mulcahy R, Hickey N. Cigarette smoking habits of patients with coronary heart disease.  Br Heart J. 1966;  28 (3) 404-408
    Suche in Google Scholar
  • 35 Doyle J T, Kannel W B, McNamara P M, Quickenton P, Gordon T. Factors related to suddenness of death from coronary disease: combined Albany-Framingham studies.  Am J Cardiol. 1976;  37 (7) 1073-1078
    Suche in Google Scholar
  • 36 Shaper A G, Wannamethee S G, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men.  Int J Epidemiol. 2003;  32 (5) 802-808
    Suche in Google Scholar
  • 37 Barnoya J, Glantz S A. Cardiovascular effects of secondhand smoke: nearly as large as smoking.  Circulation. 2005;  111 (20) 2684-2698
    Suche in Google Scholar
  • 38 Cesaroni G, Forastiere F, Agabiti N, Valente P, Zuccaro P, Perucci C A. Effect of the Italian smoking ban on population rates of acute coronary events.  Circulation. 2008;  117 (9) 1183-1188
    Suche in Google Scholar
  • 39 Sargent R P, Shepard R M, Glantz S A. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study.  BMJ. 2004;  328 (7446) 977-980
    Suche in Google Scholar
  • 40 Leng G C, Lee A J, Fowkes F G, Lowe G D, Housley E. The relationship between cigarette smoking and cardiovascular risk factors in peripheral arterial disease compared with ischaemic heart disease. The Edinburgh Artery Study.  Eur Heart J. 1995;  16 (11) 1542-1548
    Suche in Google Scholar
  • 41 Critchley J A, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review.  JAMA. 2003;  290 (1) 86-97
    Suche in Google Scholar
  • 42 Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality.  Acta Med Scand. 1987;  221 (3) 253-260
    Suche in Google Scholar
  • 43 McRobbie H, Thornley S. [The importance of treating tobacco dependence].  Rev Esp Cardiol. 2008;  61 (6) 620-628
    Suche in Google Scholar
  • 44 The Seventh Report of the Joint National Committee on Prevention .Detection, Evaluation, and Treatment of High Blood Pressure: U.S. Department of Health and Human Services. 2004: 1-86
    Suche in Google Scholar
  • 45 Wang Y, Wang Q J. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem.  Arch Intern Med. 2004;  164 (19) 2126-2134
    Suche in Google Scholar
  • 46 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.  Lancet. 2002;  360 (9349) 1903-1913
    Suche in Google Scholar
  • 47 Levy D, Merz C N, Cody R J et al.. Hypertension detection, treatment and control: a call to action for cardiovascular specialists.  J Am Coll Cardiol. 1999;  34 (4) 1360-1362
    Suche in Google Scholar
  • 48 Doumas M, Papademetriou V, Douma S et al.. Benefits from treatment and control of patients with resistant hypertension.  Int J Hypertens. 2011;  2011 318-549
    Suche in Google Scholar
  • 49 Perry Jr H M, Davis B R, Price T R et al.. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).  JAMA. 2000;  284 (4) 465-471
    Suche in Google Scholar
  • 50 Staessen J A, Thijisq L, Fagard R Systolic Hypertension in Europe (Syst-Eur) Trial Investigators et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.  J Hypertens. 2004;  22 (4) 847-857
    Suche in Google Scholar
  • 51 Grundy S M, Cleeman J I, Daniels S R American Heart Association et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.  Circulation. 2005;  112 (17) 2735-2752
    Suche in Google Scholar
  • 52 Whayne Jr T F. In defense of the metabolic syndrome.  J Clin Lipidol. 2009;  3 (4) 247-249
    Suche in Google Scholar
  • 53 NIH stops clinical trial on combination cholesterol treatment: lack of efficacy in reducing cardiovascular events prompts decision. May 26, 2011 Available at: http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792
    Suche in Google Scholar
  • 54 Clofibrate and niacin in coronary heart disease.  JAMA. 1975;  231 (4) 360-381
    Suche in Google Scholar
  • 55 Patel A, MacMahon S, Chalmers J ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2008;  358 (24) 2560-2572
    Suche in Google Scholar
  • 56 Gerstein H C, Miller M E, Byington R P Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 (24) 2545-2559
    Suche in Google Scholar
  • 57 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 (14) 977-986
    Suche in Google Scholar
  • 58 American Diabetes Association . Implications of the diabetes control and complications trial.  Diabetes Care. 2003;  26(Suppl 1) S25-S27
    Suche in Google Scholar
  • 59 Leitzmann M F, Park Y, Blair A et al.. Physical activity recommendations and decreased risk of mortality.  Arch Intern Med. 2007;  167 (22) 2453-2460
    Suche in Google Scholar
  • 60 Kujala U M, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish twin cohort.  JAMA. 1998;  279 (6) 440-444
    Suche in Google Scholar
  • 61 Hakim A A, Curb J D, Petrovitch H et al.. Effects of walking on coronary heart disease in elderly men: the Honolulu Heart Program.  Circulation. 1999;  100 (1) 9-13
    Suche in Google Scholar
  • 62 Franco O H, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease.  Arch Intern Med. 2005;  165 (20) 2355-2360
    Suche in Google Scholar
  • 63 Bijnen F C, Caspersen C J, Feskens E J, Saris W H, Mosterd W L, Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes: The Zutphen Elderly Study.  Arch Intern Med. 1998;  158 (14) 1499-1505
    Suche in Google Scholar
  • 64 Thompson P D, Buchner D, Pina I L American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).  Circulation. 2003;  107 (24) 3109-3116
    Suche in Google Scholar
  • 65 Lakka T A, Lakka H M, Rankinen T et al.. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study.  Eur Heart J. 2005;  26 (19) 2018-2025
    Suche in Google Scholar
  • 66 Howard A A, Arnsten J H, Gourevitch M N. Effect of alcohol consumption on diabetes mellitus: a systematic review.  Ann Intern Med. 2004;  140 (3) 211-219
    Suche in Google Scholar
  • 67 Wallerath T, Poleo D, Li H, Förstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects.  J Am Coll Cardiol. 2003;  41 (3) 471-478
    Suche in Google Scholar
  • 68 Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: role of TNFalpha and vascular oxidative stress.  Arterioscler Thromb Vasc Biol. 2009;  29 (8) 1164-1171
    Suche in Google Scholar
  • 69 Fisher N D, Hughes M, Gerhard-Herman M, Hollenberg N K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans.  J Hypertens. 2003;  21 (12) 2281-2286
    Suche in Google Scholar
  • 70 Maron D J. Flavonoids for reduction of atherosclerotic risk.  Curr Atheroscler Rep. 2004;  6 (1) 73-78
    Suche in Google Scholar
  • 71 Paolini J F, Mitchel Y B, Reyes R et al.. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.  Am J Cardiol. 2008;  101 (5) 625-630
    Suche in Google Scholar
  • 72 Barter P J, Caulfield M, Eriksson M ILLUMINATE Investigators et al. Effects of torcetrapib in patients at high risk for coronary events.  N Engl J Med. 2007;  357 (21) 2109-2122
    Suche in Google Scholar
  • 73 Yvan-Charvet L, Kling J, Pagler T et al.. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.  Arterioscler Thromb Vasc Biol. 2010;  30 (7) 1430-1438
    Suche in Google Scholar
  • 74 Stein E A, Roth E M, Rhyne J M, Burgess T, Kallend D, Robinson J G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.  Eur Heart J. 2010;  31 (4) 480-488
    Suche in Google Scholar
  • 75 Whayne Jr T F. What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?.  Cardiovasc Ther. 2010;  28 (2) 106-123
    Suche in Google Scholar
  • 76 Whayne T F. Vitamin D: popular cardiovascular supplement but benefit must be evaluated.  Int J Angiol. 2011;  20 (2) 63-72
    Suche in Google Scholar

Thomas F. WhayneJr. M.D. Ph.D. F.I.C.A. 

326 Wethington Building

900 South Limestone Street, Lexington, KY 40536-0200

eMail: twhayn0@uky.edu